secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2026-03-31T23:59:59+00:00
Accession:  0001999371-26-007254
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix reports Phase 1 data for Lyme prophylactic TNX-4800; Phase 2 field study planned for H1 2027
--------------------------------------------------------------------------------

- Phase 1 data (N=44) showed no significant safety signals; mean half-life 62-69 days; serum levels at 5 mg/kg ~10 μg/ml at 4 months, ~2x in vitro MEC.
- Planned Phase 2 field study: randomized, double-blind, placebo-controlled, 350 mg SC single dose; primary endpoint Lyme prevention at 4 months.
- Phase 2 expected to initiate in H1 2027 pending FDA clearance; GMP product available early 2027.
- TNX-4800 is a long-acting anti-OspA monoclonal antibody in-licensed from UMass Chan in 2025; no FDA-approved Lyme vaccine/prophylactic in US.
- If needed, controlled human infection model study planned for 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000199937126007254/0001999371-26-007254-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000199937126007254/tnxp-8k_033026.htm
  HTML page:      https://secwatch.observer/filing/0001999371-26-007254

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer